These updates are republished press releases and communications from members of the Science|Business Network. Network Updates can be sent to [email protected] and [email protected]. To know if your content piece qualifies as Network Update, check the editorial guidelines here.

Sworn enemies unite against draft EU IP law

Sworn enemies within the technology and pharmaceutical industries are joining forces in a lobbying drive to persuade European Union lawmakers to change a draft law they say will stifle innovation in Europe by criminalising patent infringements, along with all forms of intellectual property infringements.

UK spin-out spins back

Just as most public research bodies embrace commercialisation as their raison d'etre, the UK Medical Research Council is reversing the trend and taking a company it span out earlier back within its fold.

India bullish on global clinical trial business opportunity

Time and money are driving the world’s pharmaceutical companies east for their clinical trials. With its huge population, new helpful regulations and growth outstripping China, India plans to become the world leader in the clinical research business by the end of the decade.

Austrian Intercell affiliate aims to cut hospital infections

At any given time over 1.4 million people worldwide are suffering from infections they got from their health-provider, according to the World Health Organization. Pelias AG, a newly created affiliate of Austrian biotech company Intercell AG, is hoping to raise €15 million to €20 million to make a dent in those numbers.